Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for business professionals · Wednesday, August 15, 2018 · 458,771,715 Articles · 3+ Million Readers

Dynavax to Present at the RBC Capital Markets Global Healthcare Conference

BERKELEY, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that Eddie Gray, Dynavax’s chief executive officer, will participate in a fireside chat at the 2018 RBC Capital Markets Global Healthcare Conference in New York City. The presentation will be webcast live and will occur on Wednesday, February 21, 2018 at 1:35 p.m. ET.

/EIN News/ -- The live or replayed versions of the webcast will be available by visiting the “Investors” section of the Dynavax website at

About Dynavax
Dynavax is a commercial-stage biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company's first commercial product, HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the United States. Dynavax's lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development. For more information, visit


David Burke
Director, Investor Relations & Corporate Communications

Primary Logo

Powered by EIN News